Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
Terminated
Northwestern University
Phase 4
2018-03-27
Glucocorticoids are known to cause an increase in insulin resistance, leading to
hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and
outpatient setting, steroids are used for their anti-inflammatory property to treat a variety
of conditions. There is a paucity of information regarding the best way to treat
steroid-induced hyperglycemia. In this study we will compare (1) the addition of NPH insulin,
an intermediate-acting insulin, given at the time of steroid administration to the patient's
standard basal/bolus insulin to (2) modification of the standard basal-bolus insulin regimen
which will consist primarily increasing the prandial doses at lunch and supper in order to
determine which regimen is superior for glycemic control.
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
Completed
Eli Lilly and Company
Phase 1
2018-09-26
The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in
healthy Chinese participants. Blood samples will be taken to compare how the body handles the
drugs and how they affect blood sugar levels. Side effects and tolerability will be
documented. The study will last at least 18 days, not including screening. Screening is
required within 4 weeks prior to the start of the study.
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Completed
Sanofi
Phase 4
2018-10-02
The overall objective of this study is to compare the effects of Soliqua, a titratable
combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100
insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of
glucose variability using masked CGM data among people of South Asian origin living in Canada
with type 2 diabetes (T2DM).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
